Status:
COMPLETED
Precision Pharmacotherapy Smoking Cessation Program
Lead Sponsor:
Christiana Care Health Services
Collaborating Sponsors:
University of Delaware
National Institute of General Medical Sciences (NIGMS)
Conditions:
Smoking Cessation
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to determine the benefits of a personalized treatment approach, compared to a non-personalized treatment approach, for smoking cessation. In other words, this study will h...
Detailed Description
Promising new evidence suggests that applying a precision pharmacotherapy approach based on the nicotine metabolite ration (NMR), a commercially available, genetically-informed marker of nicotine meta...
Eligibility Criteria
Inclusion
- current smoker (5+ cigarettes/day)
- patient at the Helen F. Graham Cancer Center \& Research Institute (ChristianaCare) lung/thoracic clinic
Exclusion
- use of non-cigarette tobacco products or smoking cessation treatment
- psychiatric or other medical contraindications to receiving smoking cessation medication
- no telephone
- medical instability
- inability to communicate in English
- unable to consent due to mental status
- estimated life expectancy of \<6 months
- not a Delaware resident
- pregnancy
Key Trial Info
Start Date :
February 23 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2022
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT04897607
Start Date
February 23 2022
End Date
December 31 2022
Last Update
March 31 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Helen F. Graham Cancer Center & Research Institute
Newark, Delaware, United States, 19713